HIGHLIGHTS
- who: Eric Delpire and Yehezkel Ben-Ari from the Departments of Anesthesiology and Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN, USA have published the Article: A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders, in the Journal: Cells 2022, 2419 of /2022/
SUMMARY
Bumetanide (3-(butylamino)-4-phenoxy-5-sulfamoylbenzoic acid) was introduced in clinical medicine in 1972 as a drug presenting higher diuretic potency than furosemide, a compound discovered just eight years earlier. A study published in the British Medical Journal reported that in 27 edematous patients . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.